% 0期刊文章%一个克莱尔Bouvard % Nafiisha獛%卡罗尔Phan %一个拉斐尔Thuillet巴普蒂斯特骑% % Ly你%一个州%保罗罗毕拉德Marilyne Campagnac %一个Raffaella Soleti %一个弗雷德里克·埃里克·杜马斯De La罗克% % Delcambre市一个Laurent裙带% Thibaud Parpaite %一个爱丽丝Maurat %帕特里克·伯杰% jean - pierre Savineau %一个克利斯朵夫Guignabert罗杰Marthan % % Veronique Freund-Michel % Christelle吉伯特% T联接蛋白43肺动脉高压是一种很有前途的目标,因为血氧过低的肺病% D J 2019% R 10.1183/13993003.00169 -2019%欧洲呼吸杂志% P 1900169 % X肺动脉高压(PH)的机制是复杂的,多方面的,涉及不同的细胞类型,通过差距联接的渠道是相互联系的。虽然联接蛋白(Cx) -43是最丰富的缝隙连接蛋白在心脏和肺和极度控制细胞间信号交流,对PH值是未知的。本研究的重点是这样评价Cx43作为一个潜在的新的目标在Cx37 PH.Expressions Cx40, Cx43研究特发性肺动脉高血压患者肺标本(iPAH)或PH值与血氧过低的慢性肺疾病(CH-PH)。杂合的Cx43击倒CD1 (Cx43 + /−)和野生型同窝出生仔畜(Cx43 + / +)在12周的年龄小鼠被随机分为两组,其中一个是保持室内空气和其他暴露于低氧(10% O2)为3周。我们评估肺血液动力学、改造过程中心脏组织和肺动脉(PA),肺部炎症,和PA vasoreactivity。Cx43水平增加从CH-PH PA病人,而Cx43 iPAH患者减少PA水平。没有区别Cx37或Cx40指出。在缺氧治疗,Cx43 + /−老鼠部分防止慢性低氧诱导PH Cx43 + / +老鼠相比,降低肺动脉muscularisation和炎症浸润。有趣的是,自适应的改变心脏重塑Cx43 + /−老鼠不受影响。PA endothelin-1收缩是增加Cx43 + / -在常氧和缺氧条件下。总的来说,这些结果表明,针对Cx43 PH值可能有益的治疗效果而不影响补偿心脏肥大。FootnotesThis手稿最近发表在《欧洲呼吸杂志》上。 It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. bouvard has nothing to disclose.Conflict of interest: Dr. Genet has nothing to disclose.Conflict of interest: Carole PhanConflict of interest: Dr. Rode has nothing to disclose.Conflict of interest: Dr. Thuillet has nothing to disclose.Conflict of interest: Dr. TU has nothing to disclose.Conflict of interest: Dr. ROBILLARD has nothing to disclose.Conflict of interest: Dr. Campagnac has nothing to disclose.Conflict of interest: Dr. Soleti has nothing to disclose.Conflict of interest: Dr. Dumas De La Roque has nothing to disclose.Conflict of interest: Dr. Delcambre has nothing to disclose.Conflict of interest: Dr. CRONIER has nothing to disclose.Conflict of interest: Dr. Parpaite has nothing to disclose.Conflict of interest: Dr. Maurat has nothing to disclose.Conflict of interest: Dr. Berger reports grants from Nycomed, grants from Takeda, grants from Fondation du Souffle-Fonds de dotation Recherche en Santé Respiratoire, during the conduct of the study; grants and personal fees from Novartis, personal fees and non-financial support from Chiesi, grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Sanofi, personal fees from Menarinni, personal fees from TEVA, outside the submitted work.Conflict of interest: Dr. Savineau has nothing to disclose.Conflict of interest: Dr. Marthan has nothing to disclose.Conflict of interest: Dr. Guignabert has nothing to disclose.Conflict of interest: Dr. Freund-Michel has nothing to disclose.Conflict of interest: Dr. Guibert has nothing to disclose. %U //www.qdcxjkg.com/content/erj/early/2019/11/26/13993003.00169-2019.full.pdf